Study on Use of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) in Chikugo City Hospital with a View to Promoting Rational Drug Use (1)

Total Page:16

File Type:pdf, Size:1020Kb

Study on Use of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) in Chikugo City Hospital with a View to Promoting Rational Drug Use (1) 224 医 療 薬 学 Vol.30, No.3 (2004) Jpn. J. Pharm. Health Care Sci. ノ ー ト30(3)224-230 (2004) Study on Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Chikugo City Hospital with a View to Promoting Rational Drug Use (1) Hideaki Kido1, Yen Sun1, Kumiko Takaba1, Mihoko Nakashima1, Mitsuhiro Wada1, Takashi Kawada2, Hiizu Hara2 and Kenichiro Nakashima*1 Course of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University1 Chikugo City Hospital2 Received June 9, 2003 〔Accepted December 20, 2003 〕 During the period March 2000-February 2001, we conducted a study on prescriptions to determine how non-steroidal anti-inflammatory drugs (NSAIDs) were being used in Chikugo City Hospital, a medium-sized hospital, in order to promote rational drug use. The use of NSAIDs was evaluated for 10 clinical departments, together and individually. We found that Diclofenac (DIC) and sodium loxoprofen were used to about the same extent in almost all departments and that Aceta- minophen (ACE) was also prescribed as frequently as DIC. Except for ACE, no NSAIDs were used for children, particu- larly in the case of those under 9 years in age. We also evaluated the co-prescription of NSAIDs with H2-receptor antago- nists because NSAIDs are known to cause gastric adverse reactions. The number of patients who had been prescribed H2- receptor antagonists increased with patient age, especially for those over fifty years old. Zaltprofen was more frequently co- prescribed with H2-receptor antagonists than other NSAIDs. The prescription of etodolac was also found to increase with patient age, particularly so for those over fifty. Thus, we consider that information obtained by studying prescriptions can be used to evaluate the intentions of those prescribing drugs and clarify problems in the use of NSAIDs. Key words- non-steroidal anti-inflammatory drugs (NSAIDs), prescription research, rational use of drugs, drug-drug interaction PGs 8). Although COX-2 inhibitors that can inhibit only the formation of PGs being responsible for pain and inflamma- Introduction tion are required, there is no drug that can completely in- Non-steroidal anti-inflammatory drugs (NSAIDs), which hibit only COX-2. have several effects as analgesic, anti-inflammatory and anti- Recently, it has become very important to consider "ra- pyretic, are frequently and widely used clinically1). They are tional use of drug" due to the increase in interests of people actually prescribed for rheumatoid arthritis, osteoarthritis and in medical and health cares. The appropriate use of NSAIDs ankylosing spondylitis, moderate to heavy pains such as for controlling pain may be very difficult, since medical shoulder pain, menstrual pain and cramps. These pharma- providers have trouble in understanding pain rating scale for cological actions can be demonstrated by inhibiting cycloo- patients. The rating scales have been utilized to assess the xygenase (COX) activity and the following decrease of pros- pain levels of patients by many practitioners9). Other factors taglandins (PGs) biosynthesis at the site of inflammation2). for choice of NSAIDs are as follows : safety, gastrointestinal Recent studies have shown that COX has two isoenzyme pathology of the patients, whether the sickness is acute or forms, i.e. COX-1 and COX-23,4). The former protects the chronic process, and according to the type of inflammatory stomach lining and intestine, and the latter is related to the process of patients10). It is known that gastric disorder is the PGs formation in the inflammation process5-7). The main most frequent side effect of the NSAIDs. Thus, the appear- NSAID's side effect is recognized to be gastric disorders ance of a side effect is one of the most important factors to such as gastric ulcer and duodenal ulcer, which are caused evaluate the use of NSAIDs. Moreover, we have to consider by inhibiting COX-1 with a loss of local protective effects drug-drug interactions when NSAIDs are prescribed together of gastric mucosal cells and decreasing biosynthesis of with other drugs. As there are several types of pain, pre- 1 長 崎 市 文 教 町1-14; 1-14, Bunkyo-machi, Nagasaki-shi, 852-8521 Japan 2 福 岡 県 筑 後 市 大 字 和 泉917-1; 917-1, Izumi, Chikugo-shi, Fukuoka, 833-0041 Japan 医 療 薬 学 Vol.30, No.3 (2004) 225 scriptions of analgesic drugs with NSAIDs are frequently Table 1. Standard Dosage of NSAIDs. performed. Therefore, to know these interactions, monitoring of NSAIDs concentrations in blood is required. For this pur- pose, a high-performance liquid chromatography (HPLC) method is recommended. In our previous study, the simulta- neous determination ofarylpropionic acid derivatives, a group of NSAIDs, in human plasma was developed11). On the other hands, it is considered that a prescription re- search can give a significant information to a rational use of drugs. Recently, Butatsu et al. have been reported the analy- sis using prescription database for urate-lowering drugs and antiarteriosclerotic agents, and successfully evaluated the ra- tional use of drugs12'13). Thereupon, we attempted to survey how NSAIDs is actually used for considering the rational use of NSAIDs and drug-drug interaction of NSAIDs. Results and Discussions In this paper, a preliminary research to evaluate the use of NSAIDs in Chikugo City Hospital for a year (March 2000•` 1. NSAIDs used in each clinical section February 2001) is described by surveying the following ele- As shown in Fig. 1 A, DIC (30%) and LOX (29 %) were ments : 1) the practical use of NSAIDs at all or each of 10 used the most in the total amounts of NSAIDs that pre- clinical sections, 2) the practical use of NSAIDs on each scribed in all sections. The reason for this is that DIC has disorder in the special clinical section (orthopedics), 3) the many different product forms such as suppository, tablets prescription of NSAIDs with H2-receptor antagonists in or- and long-acting capsule. These product forms are adopted in thopedics. Chikugo City Hospital and the percentages for suppository, tablets and long-acting capsule were 42.7, 19.3 and 38.0%, respectively. LOX, a representative propionic acid derivative Method in NSAIDs is also prescribed very often, because it has mo- The use of NSAIDs prescribed in Chikugo City Hospital derate anti-inflammation, analgesic, and antipyretic effects from March 2000 to February 2001 is studied by using the and shows only few side effects14'15). On the other hand, data from computer for demanding clinical fees (about 2000 ACE (30%) and DIC (27%) were most frequently pre- prescriptions) to patients. This hospital has 220 beds and scribed (Fig. 1 B). Though, ACE was used most frequently consists of 10 clinical sections such as orthopedics, medi- in pediatrics, the quantity of the standard dosage adminis- cine, surgery, pediatrics, rhinolarygology, urinology, ophtha- tered to child per dose was small. lmology, brain surgery, gynecotokology and actinogenics. The total amounts of NSAIDs prescribed to outpatients Nine NSAIDs investigated in this study were sodium diclo- were largest in the orthopedics section (Fig. 2). In this sec- fenac (DIC), ampiroxicam (AMP), mefenamic acid (MEF) tion, the main symptom complained by outpatients was their etodolac (ETO), zaltprofen (ZAL), sodium loxoprofen (LOX), pain. LOX having few side effects and DIC in several pro- oxaprozin (OXA), tiaramide hydrochloride (TIA) and aceta- duct forms were prescribed in most in this hospital. The ad- minophen (ACE). vantage of the use of DIC is its strong and rapid analgesic Firstly, the use of NSAIDs prescribed for outpatients at all effect, and thus, this drug is suitable for acute pain16). Vari- and each individual clinical section was investigated. Subse- ous prescriptions can be designed on a case-by-case and se- quently, we focused on the use of NSAIDs prescribed in or- lected sustained-release form to avoid gastrointestinal disor- thopedics, especially rheumatoid arthritis, gout, herniated nu- der, and many other product forms have been released. cleus pulposis of the lumbar spine, osteoarthritis of the knee, ETO, a selective inhibitor of COX-2, has been prescribed to sciatic pain, lumbar spinal canal stenosis and osteoporosis. patients who need a long-term use due to a chronic pain. In Moreover, the use of NSAIDs prescribed with H2-receptor the medical section, ETO with few gastric side effects was antagonists in orthopedics was also examined. The particular prescribed to patients who have gastrointestinal disorder H2-receptor antagonists in this research were famotidine, risks caused by NSAIDs. The prescription frequencies of ranitidine and nizatidine. NSAIDs separated by age are shown in Fig. 3. In the under The data were presented as frequency of prescription and 19 years old groups, ACE was mostly prescribed for outpa- total amounts of the NSAIDs. NSAIDs have several dosage tients. No NSAIDs, except for ACE, were used for children and product forms, such as tablets, capsules and supposito- especially in the under 9 years old group. Though ACE is ries. The amounts of NSAIDs were summarized up in every not included in NSAIDs, it has the same effects with them. prescription, and then, divided by the standard dosage ad- Owing to the safety consideration, ACE was frequently used ministered to adult per dose. Table 1 shows the standard for children in pediatrics to reduce sudden fever17). These dosages of NSAIDs, which were used for the conversion in demonstrate that the prescription was planned to reduce the this study. side effect of NSAIDs in case of these drugs use. In this re- 226 医 療 薬 学 Vol.30, No.3 (2004) (A) (B) Fig. 1. Total Amounts (A) and Prescription Frequency (B) of NSAIDs for Chikugo City Hospital. NSAIDs, DIC : diclofenac sodium, LOX : loxoprofen sodium, MEF : mefenamic acid, ETO : etodolac, OXA : oxaprozin, AMP : ampiroxi- cam, ZAL : zaltprofen, ACE : acetaminophen, TIA : tiaramide hydro- chloride.
Recommended publications
  • United States Patent [19] [11] Patent Number: 6,149,923 Shirahase Et Al
    US006149923A United States Patent [19] [11] Patent Number: 6,149,923 Shirahase et al. [45] Date of Patent: Nov. 21, 2000 [54] ANTIRHEUMATIC AGENT OTHER PUBLICATIONS [75] Inventors: Hiroaki Shirahase, Nagaokakyo; Yoshimi et al Importance of Hydrolysis of Amino Acid Akihisa Yoshimi, Takatsuki; Fumio Moiety in Water—Soluble Prodrugs of Disodium Cromogly Fukata, Osaka; Hideki Okunishi; Yuta cate for Increased Oral Bioavailability 1992 J. Pharmaco Kobayashi, both of IZumo, all of Japan bio—Dyn 15:339—345. Mori et al Pro—drugs for the Oral Deliver of Disodium [73] Assignee: Kyoto Pharmaceutical Industries, Cromoglycate 1988 Chem. Pharm. Bull. 36:338—344. Ltd., Kyoto, Japan Primary Examiner—Thurman K. Page Appl. N0.: Assistant Examiner—Todd D. Ware 09/202,368 Attorney, Agent, or Firm—Leydig, Voit & Mayer, Ltd. PCT Filed: Jun. 6, 1997 [57] ABSTRACT PCT No.: PCT/JP97/01974 An antirheumatic agent comprising diethyl § 371 Date: Dec. 10, 1998 L-lysylcromoglycate of the following formula § 102(e) Date: Dec. 10, 1998 NH; PCT Pub. No.: WO97/47297 [87] OCOCH(CH2)4NH2 PCT Pub. Date: Dec. 18, 1997 o OCHZCHCHZO o [30] Foreign Application Priority Data Jun. 11, 1996 [JP] Japan .................................. .. 8-149549 [51] Int. Cl.7 .......................... .. A61K 9/00; A61K 31/35; A01N 43/16 H5c2ooc o o cooczns US. Cl. ......................... .. 424/400; 514/825; 514/456 Field of Search ........................... .. 424/400; 514/825, or a nontoxic salt thereof as an active ingredient. This 514/456 compound has an anti-in?ammatory action and immuno modulating action, is absorbed by oral administration to be References Cited delivered efficiently to local sites, and is associated With feWer side effects, so that it serves Well as an antirheumatic U.S.
    [Show full text]
  • Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4In Pancreatic Cancer Cells
    Research Article Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4in Pancreatic Cancer Cells Maen Abdelrahim,1,4 Cheryl H. Baker,4 James L. Abbruzzese,2 David Sheikh-Hamad,3 Shengxi Liu,1 Sung Dae Cho,1 Kyungsil Yoon,1 and Stephen Safe1,5 1Institute of Biosciences and Technology, Texas A&M University Health Science Center; 2Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center; 3Division of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas; 4Cancer Research Institute, M. D. Anderson Cancer Center, Orlando, Florida; and 5Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas Abstract through their specific interactions with VEGF receptors (VEGFR), Vascular endothelial growth factor receptor-1 (VEGFR1) is which are transmembrane tyrosine kinases and members of the expressed in cancer cell lines and tumors and, in pancreatic PDGF receptor gene family. and colon cancer cells, activation of VEGFR1 is linked to VEGFR1 (Flk-1), VEGFR2(Flt-1/KDR), and VEGFR3 (Flt-4) are the three major receptors for VEGF and related angiogenic factors. increased tumor migration and invasiveness.Tolfenamic acid, The former two receptors are primarily involved in angiogenesis in a nonsteroidal anti-inflammatory drug, decreases Sp protein endothelial cells, whereas VEGFR3 promotes hematopoiesis and expression in Panc-1 and L3.6pl pancreatic cancer cells, and lymphoangiogenesis (2, 3, 7, 8). VEGFR2 plays a critical role in this was accompanied by decreased VEGFR1 protein and angiogenesis; homozygous knockout mice were embryonic lethal mRNA and decreased luciferase activity on cells transfected [gestation day (GD) 8.5–9.0] and this was associated with the with constructs (pVEGFR1) containing VEGFR1 promoter failure to develop blood vessels (9).
    [Show full text]
  • Synthesis, Crystal Structure, and Biological Activity of Ethyl 4-Methyl-2,2-Dioxo-1H-2Λ6,1-Benzothiazine- 3-Carboxylate Polymorphic Forms
    Scientia Pharmaceutica Article Synthesis, Crystal Structure, and Biological Activity of Ethyl 4-Methyl-2,2-dioxo-1H-2λ6,1-benzothiazine- 3-carboxylate Polymorphic Forms Igor V. Ukrainets 1,* ID , Anna A. Burian 1, Vyacheslav N. Baumer 2, Svitlana V. Shishkina 2,3, Lyudmila V. Sidorenko 1 ID , Igor A. Tugaibei 4, Natali I. Voloshchuk 5 ID and Pavlo S. Bondarenko 5 1 Department of Pharmaceutical Chemistry, National University of Pharmacy, 53 Pushkinska st., 61002 Kharkiv, Ukraine; [email protected] (A.A.B.); [email protected] (L.V.S.) 2 SSI “Institute for Single Crystals”, National Academy of Sciences of Ukraine, 60 Nauki ave., 61001 Kharkiv, Ukraine; [email protected] (V.N.B.); [email protected] (S.V.S.) 3 Department of Inorganic Chemistry, V. N. Karazin Kharkiv National University, 4 Svobody sq., 61077 Kharkiv, Ukraine 4 Department of Clinical Biochemistry, Forensic Toxicology, and Pharmacy, Kharkiv Medical Academy of Postgraduate Education, 58 Amosov st., 61176 Kharkiv, Ukraine; [email protected] 5 Department of Pharmacology, N. I. Pirogov Vinnitsa National Medical University, 56 Pirogov st., 21018 Vinnitsa, Ukraine; [email protected] (N.I.V.); [email protected] (P.S.B.) * Correspondence: [email protected]; Tel.: +380-572-679-185 Received: 11 April 2018; Accepted: 21 May 2018; Published: 30 May 2018 Abstract: Continuing the search for new potential analgesics among the derivatives of 4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxylic acid, the possibility of obtaining its esters by the alkylation of the corresponding sodium salt with iodoethane in dimethyl sulfoxide (DMSO) at room temperature was studied.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Ampiroxicam Item No. 23026 CAS Registry No.: 99464-64-9 O Formal Name: carbonic acid, ethyl 1-[[2-methyl-1,1- dioxido-3-[(2-pyridinylamino)carbonyl]-2H- O O N 1,2-benzothiazin-4-yl]oxy]ethyl ester Synonym: CP 65,703 H O N MF: C20H21N3O7S FW: 447.5 O Purity: ≥98% UV/Vis.: λmax: 315 nm N Supplied as: A crystalline solid S Storage: -20°C OO Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Ampiroxicam is supplied as a crystalline solid. A stock solution may be made by dissolving the ampiroxicam in the solvent of choice. Ampiroxicam is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ampiroxicam in these solvents is approximately 10 and 20 mg/ml, respectively. Ampiroxicam is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ampiroxicam should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Ampiroxicam has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Ampiroxicam is a prodrug of piroxicam (Item No. 13368), a non-steroidal anti-inflammatory drug (NSAID) 1,2 that non-selectively and reversibly inhibits COX-1 and COX-2 (IC50s = 1.57 and 1.69 μM, respectively). Ampiroxicam is converted to piroxicam at a rate of 100, 90, 70, and 50% in humans, rats, dogs, and monkeys, respectively.1 References 1.
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • Cyclooxygenase
    COX Cyclooxygenase Cyclooxygenase (COX), officially known as prostaglandin-endoperoxide synthase (PTGS), is an enzyme that is responsible for formation of important biological mediators called prostanoids, including prostaglandins, prostacyclin and thromboxane. Pharmacological inhibition of COX can provide relief from the symptoms of inflammation and pain. Drugs, like Aspirin, that inhibit cyclooxygenase activity have been available to the public for about 100 years. Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and COX-2. Under many circumstances the COX-1 enzyme is produced constitutively (i.e., gastric mucosa) whereas COX-2 is inducible (i.e., sites of inflammation). Non-steroidal anti-inflammatory drugs (NSAID), such as aspirin and ibuprofen, exert their effects through inhibition of COX. The main COX inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs). www.MedChemExpress.com 1 COX Inhibitors, Antagonists, Activators & Modulators (+)-Catechin hydrate (-)-Catechin Cat. No.: HY-N0355 ((-)-Cianidanol; (-)-Catechuic acid) Cat. No.: HY-N0898A (+)-Catechin hydrate inhibits cyclooxygenase-1 (-)-Catechin, isolated from green tea, is an (COX-1) with an IC50 of 1.4 μM. isomer of Catechin having a trans 2S,3R configuration at the chiral center. Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. Purity: 99.59% Purity: 98.78% Clinical Data: Phase 4 Clinical Data: No Development Reported Size: 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg (-)-Catechin gallate (-)-Epicatechin ((-)-Catechin 3-gallate; (-)-Catechin 3-O-gallate) Cat. No.: HY-N0356 ((-)-Epicatechol; Epicatechin; epi-Catechin) Cat. No.: HY-N0001 (-)-Catechin gallate is a minor constituent in (-)-Epicatechin inhibits cyclooxygenase-1 (COX-1) green tea catechins.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drug-Induced Small Bowel Injuries Identified by Double-Balloon Endoscopy
    PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(31):4861-4864 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 [email protected] © 2005 The WJG Press and Elsevier Inc. All rights reserved. ELSEVIER • BRIEF REPORTS • Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy Yoshikazu Hayashi, Hironori Yamamoto, Hiroto Kita, Keijiro Sunada, Hiroyuki Sato, Tomonori Yano, Michiko Iwamoto, Yutaka Sekine, Tomohiko Miyata, Akiko Kuno, Takaaki Iwaki, Yoshiyuki Kawamura, Hironari Ajibe, Kenichi Ido, Kentaro Sugano Yoshikazu Hayashi, Hironori Yamamoto, Hiroto Kita, Keijiro Iwamoto M, Sekine Y, Miyata T, Kuno A, Iwaki T, Kawamura Sunada, Hiroyuki Sato, Tomonori Yano, Michiko Iwamoto, Y, Ajibe H, Ido K, Sugano K. Nonsteroidal anti-inflammatory Yutaka Sekine, Tomohiko Miyata, Akiko Kuno, Takaaki Iwaki, drug-induced small bowel injuries identified by double-balloon Yoshiyuki Kawamura, Hironari Ajibe, Kenichi Ido, Kentaro endoscopy. World J Gastroenterol 2005; 11(31): 4861-4864 Sugano, Department of Internal Medicine, Division of http://www.wjgnet.com/1007-9327/11/4861.asp Gastroenterology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Tochigi 329-0498, Japan Correspondence to: Hironori Yamamoto, MD, Department of Internal Medicine, Division of Gastroenterology, Jichi Medical School, Yakushiji, Minamikawachi, Tochigi 329-0498, INTRODUCTION Japan. [email protected] Adverse effects of non-steroidal anti-inflammatory drugs Telephone: +81-285-58-7348 Fax: +81-285-44-8297 (NSAIDs) in the upper and lower gastro-intestinal tract are Received: 2004-12-14 Accepted: 2005-01-05 well known[1]. In addition, NSAIDs can induce and exacerbate damage in the small bowel[2,3]. There is a study showing that 8.4% of patients taking NSAIDs developed small bowel ulcerations[4].
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]